Janus Henderson Group PLC Karuna Therapeutics, Inc. Transaction History

Janus Henderson Group PLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$161.01 - $317.85 $237,006 - $467,875	1,472 Added 10.62%	15,332 $4.85 Million
Q3 2023 Nov 14, 2023	BUY	$164.66 - $218.08 $4,445 - $5,888	27 Added 0.2%	13,860 $2.34 Million
Q2 2023 Aug 14, 2023	BUY	$176.32 - $240.22 $177,730 - $242,141	1,008 Added 7.86%	13,833 $3 Million
Q1 2023 May 15, 2023	BUY	$161.33 - $204.36 $1.18 Million - $1.5 Million	7,339 Added 133.78%	12,825 $2.33 Million
Q4 2022 Feb 14, 2023	BUY	$191.53 - $236.82 $1.05 Million - $1.3 Million	5,486 New	5,486 $1.08 Million
Q3 2022 Nov 14, 2022	BUY	$123.79 - $277.42 $120,076 - $269,097	970 Added 24.88%	4,868 $1.09 Million
Q2 2022 Aug 15, 2022	BUY	$93.97 - $143.33 $3,007 - $4,586	32 Added 0.83%	3,898 $493,000
Q1 2022 May 16, 2022	BUY	$98.9 - $132.37 $593 - $794	6 Added 0.16%	3,866 $490,000
Q4 2021 Feb 14, 2022	BUY	$110.64 - $159.4 $215,084 - $309,873	1,944 Added 101.46%	3,860 $506,000
Q3 2021 Nov 16, 2021	BUY	$101.2 - $125.87 $193,899 - $241,166	1,916 New	1,916 $235,000

332K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.